Inebilizumab

Therapeutic indications

Inebilizumab is indicated for:

Neuromyelitis optica spectrum disorders, anti-aquaporin-4 immunoglobulin G seropositive patients

Population group: only adults (18 years old or older)

Inebilizumab is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300 mg once followed 2 weeks later by 300 mg, and thereafter 300 mg once every 6 months

Contraindications

Inebilizumab is contraindicated in the following cases:

Severe active infection

Infectious disease

Active or untreated latent tuberculosis

Tuberculosis

History of progressive multifocal leukoencephalopathy (PML)

Progressive multifocal leukoencephalopathy

Severely immunocompromised state

at least one of

Immunodeficiency
Patient immunocompromised

Active malignancies

Malignant tumour

Vaccinations

Vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.